Use your antibodies-online credentials, if available.
Il n’y a pas de produits dans votre liste de comparaison.
Votre panier est vide.
Afficher toutes les espèces
Afficher tous les synonymes
Sélectionnez vos espèces et l'application
anti-Mouse (Murine) SPRED1 Anticorps:
anti-Human SPRED1 Anticorps:
anti-Rat (Rattus) SPRED1 Anticorps:
Vous arrivez à notre recherche pré-filtrée.
Human Polyclonal SPRED1 Primary Antibody pour ICC, IF - ABIN4355739
Baras, Gandhi, Munari, Faraj, Shultz, Marchionni, Schoenberg, Hahn, Hoque, Hoque, Berman, Bivalacqua, Netto: Identification and Validation of Protein Biomarkers of Response to Neoadjuvant Platinum Chemotherapy in Muscle Invasive Urothelial Carcinoma. dans PLoS ONE 2015
Cosuppression of Sprouty and Sprouty-related negative regulators of FGF signalling in prostate cancer
SPREDs promote self-renewal and inhibit mesodermal differentiation of murine ES cells by selective suppression of the ERK/MAPK (Montrer MAPK1 Anticorps) signaling pathway in pluripotent cells
The data suggest that Spred1 negatively regulates group 2 innate lymphoid cell development and functions through the suppression of the Ras-ERK (Montrer EPHB2 Anticorps) pathway.
Microrna-126 was transported into recipient human coronary artery endothelial cells by endothelial microparticles and functionally regulated the target protein sprouty-related, EVH1 domain-containing protein 1 (SPRED1).
show that neurofibromin (Montrer NF1 Anticorps), the NF1 (Montrer NF1 Anticorps) gene product, is a Spred1-interacting protein that is necessary for Spred1's inhibitory function
The results suggest that Spred1 negatively regulates mast cell activation, which is modulated by miR126.
SPRED1 is a likely substrate of SHP2 (Montrer PTPN11 Anticorps), whose tyrosine dephosphorylation is required to attenuate the inhibitory action of SPRED1 in the Ras/ERK (Montrer EPHB2 Anticorps) pathway.
Data show that both SPRED1 and SPRED2 (Montrer SPRED2 Anticorps) inhibit the ability of DYRK1A (Montrer DYRK1A Anticorps) to phosphorylate its substrates.
These data suggest that Spreds are key regulators of RhoA (Montrer RHOA Anticorps)-mediated cell motility and signal transduction. Furthermore, our study suggests that the induction of Spreds could be a novel strategy for preventing cancer cell metastasis.
Spred-1 and Spred-2 (Montrer SPRED2 Anticorps) were found to be expressed predominantly in brain
The EVH1 domain of Spred1 binds to the noncatalytic portion of the GAP-related domain of neurofibromin (Montrer NF1 Anticorps).
Results provide genetic evidence that miR (Montrer MLXIP Anticorps)-126, through its target gene Spred-1, plays a critical role in the development of retinal vascular layers.
In one case we identified a nonsense mutation c.46C>T (p.Arg16*) in exon 2 of SPRED1 gene, confirming diagnosis of Legius syndrome. This mutation was reported previously.
PURA (Montrer PURA Anticorps) may be a potential target of miR (Montrer MLXIP Anticorps)-144 and observed downregulation of PURA (Montrer PURA Anticorps) may be caused by increased expression of miR (Montrer MLXIP Anticorps)-144. The other predicted target of miR (Montrer MLXIP Anticorps)-144 SPRED1, was found to be downregulated in 69 per cent EC tissues as compared to matched distant non-malignant tissues.
Data suggest SPRED1 EVH1 domain interacts with NF1 (Montrer NF1 Anticorps) GRD domain [N-term. 16AA/C-term. 20AA of GTPase-activating protein (Montrer RASA1 Anticorps)-related domain]; SPRED1 EVH1 and NF1 (Montrer NF1 Anticorps) GRD mutations observed in Legius syndrome reduce binding affinity between EVH1/GRD domains.
SPRED1 decreased expression correlated with genetic features of AML (Montrer RUNX1 Anticorps). Our study reveals a new mechanism which contributes to deregulate RAS MAPK (Montrer MAPK1 Anticorps) pathway in the vast majority of paediatric AMLs
Antisense-mediated knockdown (anti-miR (Montrer MLXIP Anticorps)) revealed that miR (Montrer MLXIP Anticorps)-206/21 coordinately promote RAS-ERK (Montrer EPHB2 Anticorps) signaling and the corresponding cell phenotypes by inhibiting translation of the pathway suppressors RASA1 (Montrer RASA1 Anticorps) and SPRED1.
SPRED1 seems to play an important role in recruiting neurofibromin (Montrer NF1 Anticorps) to the plasma membrane. (Review)
Older age and deletions of IKZF1 (Montrer IKZF1 Anticorps) and SPRED1 were also associated with poor overall survival of pediatric B-cell precursor acute lymphoblastic leukemia.
The protein encoded by this gene is a member of the Sprouty family of proteins and is phosphorylated by tyrosine kinase in response to several growth factors. The encoded protein can act as a homodimer or as a heterodimer with SPRED2 to regulate activation of the MAP kinase cascade. Defects in this gene are a cause of neurofibromatosis type 1-like syndrome (NFLS).
sprouty-related, EVH1 domain-containing protein 1
, sprouty-related protein with EVH-1 domain 1
, sprouty-related, EVH1 domain containing 1
, sprouty-related, EVH1 domain-containing protein 1-like
, sprouty-related protein 1 with EVH-1 domain
, suppressor of Ras/MAPK activation
, sprouty protein with EVH-1 domain 1, related sequence